Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of carfilzomib (ONO-7057) in relapsed/refractory multiple myeloma
jRCT2080221530Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2011
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by Ono Pharmaceutical. Primary endpoints: Safety and tolerability of carfilzomib (ONO-7057), Pharmacokinetics of carfilzomib (ONO-7057) and 2 more. Started Aug 2011; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080221530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221530.